• Immunogenicity Assessment

    • Therapeutic In Silico Services
      • ISPRI™ Website
      • ISPRI Downselect™
      • ISPRI Quantify™
      • ISPRI Analyze™
      • ISPRI Evaluate™
      • ISPRI-HCP™
      • ISPRI Design™
      • PANDA® Screening
    • Vaccine In Silico Services
      • iVAX™
      • EpiCC™
      • Ancer®
      • PreVAX™
    • Lab Services
      • HLA Binding Assay
      • Naive CD4+ T Cell Assay
      • Innate Assay
    • Consulting Services
  • About Us
    • Leadership
    • Careers
  • Partner
  • Press
    • News
    • Events
    • Publications
    • Blog
  • Contact Us
Providence-Based Biotech Startup, EpiVax, Celebrates 25th Anniversary

Providence-Based Biotech Startup, EpiVax, Celebrates 25th Anniversary

by Elena Iemma | May 17, 2023 | News

PROVIDENCE, RI, May 17, 2023 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) is celebrating its 25th birthday by renewing the company’s commitment to improving human health everywhere while highlighting the development of groundbreaking tools by the company. In addition,...
EpiVax and Zoetis to Collaborate on Swine T cell Epitope Prediction Tool: CircoMatch™

EpiVax and Zoetis to Collaborate on Swine T cell Epitope Prediction Tool: CircoMatch™

by Elena Iemma | Jan 10, 2023 | News

PROVIDENCE, RI, January 10, 2023 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) and Zoetis, are pleased to announce an exclusive collaboration to develop CircoMatch™, a unique bioinformatics tool that predicts the coverage of Porcine Circovirus Type 2 (PCV2) vaccines...
EpiVax worked for 21 years to be able to make a vaccine in 24 hours!

EpiVax worked for 21 years to be able to make a vaccine in 24 hours!

by Adam | Feb 10, 2020 | News

COVID-19 Coverage EpiVax is dedicated to providing continuously updated information concerning COVID-19 vaccine efforts. For all updates, press releases, interviews and more please visit our official COVID-19 page. Click here UPDATE March 16, 2020:   As closures and...

Recent Posts

  • The Platinum Vaccine & Change is Good!
  • EpiVax Appoints Dr. Vibha Jawa to Lead Scientific Strategy as CSO
  • The Amsterdam Immunogenicity & Tolerance Seminar: 2025
  • The Westin Immunogenicity Seminar
  • Is “Artificial” Intelligence an Option for your ADA ?

Recent Comments

No comments to show.

Join our newsletter

Stay up to date with EpiVax and greater industry news, events, and technological advancements with this monthly update written by EpiVax co-founder and CMO, Dr. Annie De Groot.

Explore

Therapeutic In Silico Services

Vaccine In Silico Services

Lab Services

Consulting

LinkedIn

About Us

Careers

Partner

News

Events

Publications

Contact Us

We use cookies to ensure that we give you the best experience on our website. By clicking 'accept', you consent to our use of cookies.AcceptDecline